raddar to Become a Mass-Media Platform with National Scale and Local Precision 
Dynabook Portégé Z40L-N: The No-Dongle Travel Companion Your Staff (And You!) Actually Need Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif., Aug. 10, 2021…
Zosano Pharma Reports Second Quarter 2021 Financial Results
FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance
DURHAM, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug….
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Commenced dosing in Phase 3 PATHFNDR-1 study – – Phase 1 single-ascending dose data…
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
CB4211 was well-tolerated and appeared safe with no serious adverse events Robust reductions in ALT…
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218…
POINT Biopharma Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC
INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT), a company…
Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous…
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference…
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021….
Letter to Shareholders from the Chairman of the Board Ilya Shpurov
Nicosia, Cyprus, Aug. 10, 2021 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC: (RAFA) shares the…
Cosmos Holdings to Open Flagship Store on Alibaba’s Tmall Global, World’s Largest Cross-Border E-Commerce Marketplace with 500M Monthly Active Users
Company Partners with Leading China E-Commerce Solutions Provider REMAI to Launch Sky Premium Life Products…
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”),…
Medexus Schedules First Quarter Fiscal 2022 Conference Call
TORONTO and CHICAGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or…
Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021
MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA,…
Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families
Mindset has identified several potential leads across its psilocybin/psilocin and DMT/5-MeO-DMT analogs that demonstrate superior…
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion…
Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for…